Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Operational Planning Guidance

    Headshot of Sarah Theobald with text reading 'Healthcare communications trends in 2026'

    What will healthcare communications look like in 2026? Amiculum’s prediction of upcoming trends

    By Sarah Theobald

    Amiculum

    - PMLiVE

    UK and US agree on landmark pharma pricing tariff deal

    US tariffs on UK-produced pharmaceuticals will remain at zero for three years

    - PMLiVE

    Does real-world use of AI in systematic literature reviews result in time and cost savings?

    By Manca Povsic and Emma Griffiths

    Amiculum

    Quote from the article: Without adapting JCA to include assessment of real-world data and broader benefits, vaccines may be undervalued

    Is Joint Clinical Assessment (JCA) appropriate for assessing the broader value of vaccines?

    By Emily Morton-West

    Amiculum

    Genesis giveaway of a minifigure

    Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212

    Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10...

    Genesis Research Group

    - PMLiVE

    Minds + Assembly Launches Assembled Intelligence and Adds Stratevi to Expand Market Access and HEOR Solutions

    New York, NY — 10.23.2025 — Minds + Assembly, a leading healthcare marketing firm, today announced the launch of Assembled Intelligence, an integrated communications and commercialization platform designed to unite...

    BOLDSCIENCE

    - PMLiVE

    ViiV Healthcare receives NICE recommendation for HIV prevention therapy

    The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales

    - PMLiVE

    Uniphar On Track to Achieve SBTi Target of Halving Scope 1 and 2 Emissions by 2030

    [Dublin, 9th October 2025] Uniphar, a global leader in pharmaceutical and medtech solutions, is making progress towards its near-term Science Based Targets initiative (SBTi) goal of halving Scope 1 and...

    Uniphar

    - PMLiVE

    New National Commission launched to strengthen AI regulation

    The Commission will unite healthcare leaders, regulators and technology experts to shape future AI governance

    Streamlining European expansion for cell and gene therapies

    Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs). Europe...

    Uniphar

    - PMLiVE

    Current CGT landscape and future outlook  

    What makes CGT unique  Cell and gene therapy (CGT) is a unique treatment that uses cells and genetic material to treat and cure diseases. Personalized to the patient, CGT’s offer...

    Uniphar

    - PMLiVE

    Building for Success: Aligning Preclinical and Phase 1 Strategy with Commercial Goals 

    This article concludes our three-part series on preparing cell and gene therapies (CGTs) for successful launch and long-term viability. The first article explored the unique scientific and logistical challenges of...

    Uniphar

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links